Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

scPharmaceuticals Inc. - Common Stock (NQ: SCPH )

3.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20
Open 3.020
Bid (Size) 2.880 (1)
Ask (Size) 3.300 (1)
Prev. Close 3.020
Today's Range 3.020 - 3.020
52wk Range 2.750 - 6.200
Shares Outstanding 35,769,073
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wondering what's happening in today's after-hours session?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
From scPharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
-15.41%
-15.41%
1 Month
-9.85%
-9.85%
3 Month
-11.18%
-11.18%
6 Month
-40.90%
-40.90%
1 Year
-43.66%
-43.66%

More News

Read More
Earnings Scheduled For November 13, 2024
Via Benzinga
scPharmaceuticals's Earnings Outlook
Via Benzinga
SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Recap: scPharmaceuticals Q4 Earnings
Via Benzinga
A Preview Of scPharmaceuticals's Earnings
Via Benzinga
Recap: scPharmaceuticals Q3 Earnings
Via Benzinga
Earnings Preview: scPharmaceuticals
Via Benzinga
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization
Via Benzinga
Exposures Product Safety
7 Short-Squeeze Stocks That Could Beat Down the Bears
Via InvestorPlace
SCPH Stock Earnings: scPharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Outlook For scPharmaceuticals
Via Benzinga
The Latest Analyst Ratings for scPharmaceuticals
Via Benzinga
Analyst Ratings for scPharmaceuticals
Via Benzinga
Earnings Scheduled For March 13, 2024
Via Benzinga
Dow Up 150 Points; Gold Jumps Over 2%
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Earnings Scheduled For August 10, 2023
Via Benzinga
Earnings Outlook For scPharmaceuticals
Via Benzinga
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Nasdaq Surges Over 2%; Accenture To Reduce 19,000 Jobs
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.